SANTEN PHARMACEUTICAL CO.,LTD. FY2026 FY Earnings Report

クイックビュー

Executive Summary

For the fiscal year ending March 2026, Santen Pharmaceutical recorded Revenue of ¥2,916B (YoY -¥84B, -2.8%), resulting in Operating Income of ¥478B (YoY +¥9B, +2.0%) and Net Income of ¥376B (YoY +¥17B, +4.8%). The revenue decline was mainly driven by demand adjustment in the domestic market with the Japan segment contracting by -11.2%, partially offset by overseas growth in EMEA +7.8% and Asia +14.0%. Gross profit margin improved to 58.2% (up +2.1pt from 56.1%) due to a favorable product mix, which absorbed an increase in SG&A ratio to 30.7% (up +1.4pt), maintaining an Operating Income margin of 16.4% (up +0.8pt). Ordinary Income of ¥220B (YoY -¥42B, -16.1%) was pressured by an equity-method loss of -¥6.8B and deterioration in financial results (financial expenses ¥19.9B > financial income ¥16.4B), but a reduced effective tax rate of 20.8% lowered tax burden and Net Income exceeded the prior year. Operating Cash Flow was ¥435B (YoY -28.6%) though FCF remained at ¥305B. Total shareholder returns amounted to ¥455B (dividends ¥126B and share buybacks ¥328B), representing a Total Return Ratio of approximately 121%.

業績変動要因

【Revenue】Revenue of ¥2,916B (YoY -2.8%) declined primarily due to an adjustment phase in the domestic prescription pharmaceutical market. By region, Japan decreased significantly to ¥1,468B (-11.2%), and sales to two major wholesalers also fell year-on-year (Suzuken ¥370B, Mediceo ¥300B), suggesting distribution inventory adjustment. Overseas performance was solid with EMEA ¥801B (+7.8%), Asia (ex-China) ¥333B (+14.0%), and China ¥300B (+0.5%), demonstrating the benefit of geographic diversification. By product, prescription pharmaceuticals (¥2,656B, -4.0%) remained the core but slowed, while medical devices ¥119B (+22.3%) and OTC pharmaceuticals ¥122B (+5.1%) supported growth. Gross profit margin improved to 58.2% (up +2.1pt from 56.1%), reflecting a shift toward higher-value products and pricing measures.

【Profitability】Operating Income of ¥478B (+2.0%) benefitted from improved gross margin, absorbing higher SG&A (¥896B, +1.8%) to deliver higher operating profit. SG&A ratio rose to 30.7% (up +1.4pt from 29.3%), reflecting increased growth investments (promotion, personnel, logistics, etc.). R&D expense was ¥262B (9.0% of Revenue), up +8.6% YoY, but remains below the pharma industry standard (15–20%). Non-operating items were negative as financial expenses of ¥20B exceeded financial income of ¥16B and an equity-method investment loss of ¥6.8B contributed to Ordinary Income of ¥220B (YoY -16.1%). In extraordinary items, other income of ¥70B (including ¥57B reclassification gain on cumulative translation adjustments of foreign operations) was recognized, offset by other expenses of ¥44B (including impairment losses of ¥38B), resulting in Profit Before Tax of ¥474B (approx. flat YoY, -0.1%). Corporate taxes were ¥99B (effective tax rate 20.8%), reduced by ¥11.6B YoY, yielding Net Income of ¥376B (+4.8%). In conclusion, despite revenue decline, improved gross margin and one-off income items lifted Net Income, resulting in an income-expanding result amid lower top-line.

セグメント別分析

The company operates a single segment (ophthalmic healthcare); thus, segmented operating profit disclosure is not provided. Revenue composition by region was Japan 50.3%, EMEA 27.5%, Asia (ex-China) 11.4%, China 10.3%, bringing overseas ratio to about 50%. Japan’s share declined from 55.1% YoY, reflecting increased overseas diversification.

主要財務指標

【Profitability】Operating margin of 16.4% (up +0.8pt from 15.6%) was supported by improvement in gross profit margin to 58.2% (up +2.1pt), offsetting an increase in SG&A ratio to 30.7% (up +1.4pt). Net margin improved to 12.9% (up +0.7pt from 12.2%), and ROE rose to 12.8% (up +0.6pt from 12.2%). R&D ratio at 9.0% is below industry norm and supports short-term earnings but poses challenges to mid-to-long-term pipeline depth. 【Cash Quality】Operating Cash Flow of ¥435B was 1.16x Net Income (¥376B), indicating healthy cash conversion. Working capital showed a notable buildup in inventories of ¥646B (up +25.2% from ¥516B), with Days Inventory Outstanding (DIO) at 193 days and Cash Conversion Cycle (CCC) at 177 days, signaling deterioration in efficiency. Days Sales Outstanding (DSO) was stable at 90 days, while Days Payable Outstanding (DPO) shortened to 106 days, indicating room to improve working capital management. 【Investment Efficiency】Total asset turnover was low at 0.69x, but Equity Ratio remained high at 70.2% (up +0.3pt from 69.9%), preserving strong safety. Tangible fixed asset turnover was 3.7x and intangible asset ratio was 16.9%, indicating balanced asset composition. 【Financial Soundness】D/E ratio was 0.43x, current ratio 260%, and cash and cash equivalents totaled ¥809B, ensuring ample liquidity. Interest coverage was about 10x (EBIT ¥205B ÷ interest expense ¥13B), indicating sufficient interest-servicing capacity.

キャッシュフロー分析

Operating Cash Flow was ¥435B (YoY ¥609B, -28.6%) but remained 1.16x Net Income (¥376B). Subtotal (before working capital changes) was ¥511B, with working capital movements of -¥76B driven mainly by inventory increase of -¥100B and decrease in payables of -¥44B. After corporate tax payments of ¥74B, interest payments of ¥13B, and lease payments of ¥33B, Operating Cash Flow totaled ¥435B. Investing Cash Flow was -¥130B, with capital expenditures of -¥68B and intangible asset acquisitions of -¥74B as main items, partially offset by proceeds from sale of intangible assets of ¥10B. FCF was ¥305B (YoY ¥528B, -42.2%) but covered dividends of ¥126B (FCF/dividend 2.4x). Financing Cash Flow was -¥493B, driven by share buybacks of -¥328B, dividend payments of -¥126B, and lease liability repayments of -¥33B. Total shareholder returns (dividends + buybacks) were approximately ¥455B, exceeding FCF ¥305B by about ¥150B and funded by a drawdown of cash balance. Including foreign exchange translation effect of +¥67B, cash and cash equivalents decreased to ¥809B (YoY ¥930B, -¥121B). Normalization of working capital (particularly inventories) is key to CF improvement next fiscal year.

収益の質

There is a gap between Operating Income (¥478B) and Ordinary Income (¥220B) of approximately ¥258B, attributable to deterioration in non-operating items. Financial expenses of ¥20B exceeded financial income of ¥16B, and equity-method investment losses of ¥6.8B contributed to non-operating losses totaling -¥258B. In extraordinary items, other income of ¥70B (including ¥57B reclassification gain on cumulative translation adjustments of foreign operations) was recognized, offset by other expenses of ¥44B (including impairment losses of ¥38B), producing Profit Before Tax of ¥474B. The reclassification gain is a one-off factor; Ordinary Income of ¥220B should be viewed as a more sustainable indicator of earnings power. Comprehensive income of ¥555B substantially exceeded Net Income of ¥376B; the difference of ¥179B was mainly due to foreign currency translation differences of ¥136B, remeasurements of defined benefit plans of ¥19B, and net changes in fair value through OCI financial assets of ¥25B. While Operating Cash Flow exceeding Net Income indicates good accrual quality, the significant inventory increase embeds potential future impairment risk, warranting attention to sustainability.

業績予想・ガイダンス

Full year guidance is Revenue ¥3,110B (vs current year +6.6%), Operating Income ¥495B (+3.6%), and Net Income ¥395B (+5.2%), projecting revenue and earnings growth. Progress against current year results is high: Revenue 93.8%, Operating Income 96.6%, Net Income 95.1%, indicating a high probability of achieving full-year targets. Assumptions for growth include normalization of inventory adjustments in Japan and continued overseas (EMEA, Asia) growth. Operating Income growth is expected to lag Revenue due to ongoing growth investments (SG&A) and limited upside in gross margin improvement. Forecast EPS is ¥124.42 (vs current ¥114.04, +9.1%), forecast dividend ¥21 (no change from current mid- and year-end split assumption of midterm ¥19, totaling effectively similar cash), with a forecast payout ratio of about 16.9%, which is conservative. Next fiscal year may see a reduction in Total Return Ratio from the current level (approx. 121%) and a shift toward shareholder returns funded within FCF.

株主還元

Current fiscal year dividend was ¥38 per share (interim ¥19, year-end ¥19), with a payout ratio of 33.3% (dividends total ¥126B vs Net Income ¥376B). Forecast dividend for next fiscal year is ¥21; with forecast EPS ¥124.42, the payout ratio is about 16.9%, a conservative level. FCF of ¥305B covers dividend total ¥126B (FCF/dividend 2.4x), supporting dividend sustainability. Meanwhile, share buybacks totaled ¥328B and cancellation of treasury shares of ¥368B was executed, reducing treasury stock balance to ¥10B (from ¥12B). Total shareholder returns (dividend ¥126B + buybacks ¥328B) amounted to approximately ¥455B, yielding a Total Return Ratio of about 121% (vs Net Income ¥376B). Since total returns exceeded FCF ¥305B by about ¥150B, cash balance declined to ¥809B (from ¥930B, -¥121B). Given ample cash and stable Operating Cash Flow, this is manageable in the short term, but sustaining such a high Total Return Ratio going forward depends on expanding FCF (working capital normalization).

リスク要因

1. Working capital efficiency deterioration risk: Inventories ballooned to ¥646B (YoY +25.2%), with DIO 193 days and CCC 177 days, significantly worsening efficiency. Prolonged demand adjustment or product obsolescence could trigger impairment losses affecting both profits and cash flow. Payables decreased by ¥44B YoY, and changes in supplier payment terms may further pressure working capital. Delays in inventory normalization could reduce FCF and increase liquidity risk.

2. Domestic demand decline and slowdown of core products: Japan segment revenue fell to ¥1,468B (-11.2%), and prescription pharmaceuticals declined to ¥2,656B (-4.0%), indicating deceleration in core areas. Price revisions, generic penetration, and competitive entrants may structurally reduce domestic market profitability. With R&D ratio at 9.0% below industry norms, there is concern that insufficient investment may impair new product generation and mid-to-long-term competitiveness.

3. Overseas profitability and FX risk: EMEA and Asia now account for about 40% of Revenue, and higher overseas exposure increases sensitivity to currency movements. This fiscal year, foreign currency translation differences of +¥136B were recorded in OCI; in a yen-strengthening scenario, the opposite valuation losses could occur. Changes in foreign pricing/regulatory regimes could also hurt overseas profitability. Financial results were negative (financial expenses ¥20B > financial income ¥16B); in a rising interest rate environment, interest burden could increase.

業種ベンチマーク（参考・当社調べ）

収益性・リターン

Profitability metrics substantially exceed industry medians, indicating top-tier profitability within the pharmaceutical sector.

成長性・資本効率

Revenue growth is slightly below the industry median, but given wide dispersion across the sector, the company’s relative position is approximately mid-ranking.

※Source: Company aggregation

決算上の注目ポイント

1. Despite revenue decline, improvement in gross margin and price/mix strategy delivered Operating Income growth, placing profitability among the upper ranks in the pharmaceutical industry. The company maintains a strong financial profile with Operating Income margin 16.4%, Net margin 12.9%, ROE 12.8%, Equity Ratio 70.2%, D/E 0.43x, and cash ¥809B, offering short-term earnings stability and defensive characteristics.

2. However, the significant inventory increase (+25.2%) and deterioration of working capital efficiency (CCC 177 days) warrant caution. If inventories (¥646B) fail to normalize, sustained FCF generation could be impaired, making it difficult to maintain a Total Return Ratio of 121%. Inventory turnover improvement and recovery in Operating Cash Flow next fiscal year are key to sustaining shareholder returns.

3. R&D ratio of 9.0% is well below the industry standard (15–20%); while it supports short-term profits, it raises questions about mid-to-long-term pipeline robustness. Overseas revenue share nearing 50% enhances geographic diversification, but with slowing core prescription pharmaceuticals, the balance between next-generation product creation and R&D investment intensity will determine future growth sustainability. The next-year guidance is growth-oriented but depends on both domestic recovery and overseas expansion, necessitating close monitoring of achievement.

---

This report is an AI-generated earnings analysis produced by analyzing XBRL financial statement data. It does not constitute a recommendation to invest in specific securities. Industry benchmarks are reference information aggregated by the firm based on public financial statements. Investment decisions are your responsibility; consult a professional advisor as needed.